News

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...
Despite the indication of a potential risk, people who receive abnormal results on blood-based colorectal screening tests commonly do not receive the follow-up colonoscopy.
A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...
James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...
Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.
Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.
Van Der Beek offered a reminder that colorectal cancer is one of the most curable types of cancer when it’s caught early and ...
Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...
Guardant Health (GH) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.48 per share a year ago. These figures are ...